ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,031Medicare Part D Prescriptions Filled, Including Refills

Rank: 294 out of 1844

$497K Total Retail Price of All Prescriptions

Rank: 361 out of 1844

274 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
80% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 274 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 274 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 8,641 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
NAMENDA 366 366 1 33
AMLODIPINE BESYLATE 285 263 2 6
HYDROCODONE-ACETAMINOPHEN 266 262 S3 3 2
FUROSEMIDE 262 243 4 7
DONEPEZIL HCL 254 254 5 26
LISINOPRIL 245 234 6 4
LEVOTHYROXINE SODIUM 233 232 7 1
PRAVASTATIN SODIUM 225 216 8 10
MIRTAZAPINE 222 215 9 49
WARFARIN SODIUM 192 157 10 13
GABAPENTIN 175 168 11 15
CARVEDILOL 164 149 12 22
SERTRALINE HCL 159 159 13 21
CITALOPRAM HBR 156 154 14 19
SIMVASTATIN 153 124 15 3
OMEPRAZOLE 135 123 16 5
TRAMADOL HCL 132 132 17 18
FAMOTIDINE 129 129 18 63
METOPROLOL TARTRATE 128 123 19 11
DIVALPROEX SODIUM 126 125 20 74
POTASSIUM CHLORIDE 123 123 21 16
GLIPIZIDE 121 108 22 70
EXELON 109 109 23 112
LANTUS 102 101 24 42
HYDROCHLOROTHIAZIDE 101 100 25 9
LEVETIRACETAM 100 99 26 105
METFORMIN HCL 98 87 27 8
ESCITALOPRAM OXALATE 95 85 28 52
TAMSULOSIN HCL 93 92 29 27
NITROFURANTOIN MONO-MACRO 86 86 30 151
QUETIAPINE FUMARATE 85 85 31 82
RANITIDINE HCL 84 68 32 38
RISPERIDONE 81 81 33 65
PANTOPRAZOLE SODIUM 78 78 34 32
ZOLPIDEM TARTRATE 74 74 35 23
CARBIDOPA-LEVODOPA 68 68 36 86
ATENOLOL 67 61 37 17
CYMBALTA 65 57 38 36
TRAZODONE HCL 65 65 38 43
LIDODERM 63 63 40 155
LACTULOSE 61 61 41 171
NOVOLIN R 60 57 42 214
KLOR-CON M10 59 56 43 149
LEVOFLOXACIN 56 56 44 78
GLIMEPIRIDE 55 55 45 35
CLOPIDOGREL 54 54 46 34
SPIRIVA 52 52 47 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 9, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.